An Open Label, Single Arm, Multicentre Study to Assess the Clinical Effectiveness and Safety of Lynparza (Olaparib) Capsules Maintenance Monotherapy in Platinum Sensitive Relapsed Somatic or Germline BRCA Mutated Ovarian Cancer Patients Who Are in Complete or Partial Response Following Platinum Based Chemotherapy (ORZORA)
Phase of Trial: Phase IV
Latest Information Update: 09 Oct 2017
At a glance
- Drugs Olaparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Acronyms ORZORA
- Sponsors AstraZeneca
- 04 Oct 2017 Planned End Date changed from 2 Jan 2019 to 3 Jun 2019.
- 04 Oct 2017 Planned primary completion date changed from 2 Jan 2019 to 3 Jun 2019.
- 30 Sep 2016 Planned number of patients changed from 250 to 275.